financetom
Business
financetom
/
Business
/
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise
Apr 22, 2024 7:20 AM

09:56 AM EDT, 04/22/2024 (MT Newswires) -- Guardant Health ( GH ) said Monday that a panel of the US Food and Drug Administration Medical Devices Advisory Committee will review the premarket approval application for its Shield blood test for colorectal cancer screening on May 23.

Shares of the company rose 7.7% in recent trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tyson Foods Divests Georgia Plant In Profitability Push
Tyson Foods Divests Georgia Plant In Profitability Push
Jul 10, 2024
Tyson Foods, Inc. ( TSN ) announced its agreement to sell its poultry complex in Vienna, Georgia, to House of Raeford Farms. The financial details of the transaction were not revealed. This move is part of Tyson Foods’ ongoing strategy to optimize its plant network. Despite the sale, Tyson Foods ( TSN ) will continue to meet customer demands through...
BRIEF-Honeywell To Acquire Air Products' Liquefied Natural Gas Process Technology And Equipment Business To Expand Energy Transition Solutions And Services
BRIEF-Honeywell To Acquire Air Products' Liquefied Natural Gas Process Technology And Equipment Business To Expand Energy Transition Solutions And Services
Jul 10, 2024
July 10 (Reuters) - Air Products and Chemicals Inc ( APD ) : * HONEYWELL TO ACQUIRE AIR PRODUCTS' LIQUEFIED NATURAL GAS PROCESS TECHNOLOGY AND EQUIPMENT BUSINESS TO EXPAND ENERGY TRANSITION SOLUTIONS AND SERVICES * HONEYWELL INTERNATIONAL INC ( HON ): PROPOSED DEAL FOR FOR $1.81 BILLION IN AN ALL-CASH TRANSACTION * HONEYWELL INTERNATIONAL ( HON ): DEAL EXPECTED TO...
BRIEF-Amylyx Pharmaceuticals Announces Acquisition Of Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide) With FDA Breakthrough Therapy Designation
BRIEF-Amylyx Pharmaceuticals Announces Acquisition Of Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide) With FDA Breakthrough Therapy Designation
Jul 10, 2024
July 10 (Reuters) - Amylyx Pharmaceuticals Inc ( AMLX ): * AMYLYX PHARMACEUTICALS ANNOUNCES ACQUISITION OF PHASE 3-READY GLP-1 RECEPTOR ANTAGONIST (AVEXITIDE) WITH FDA BREAKTHROUGH THERAPY DESIGNATION * AMYLYX PHARMACEUTICALS INC ( AMLX ) - AVEXITIDE TO ENTER PHASE 3 TRIALS IN Q1 2025 * AMYLYX PHARMACEUTICALS ( AMLX ): ENGAGING IN TALKS WITH BROADER CONGENITAL HI COMMUNITY TO DEVELOP...
BRIEF-State Street Corp Reports 4.32% Passive Stake In Novavax Inc As Of June 30, 2024
BRIEF-State Street Corp Reports 4.32% Passive Stake In Novavax Inc As Of June 30, 2024
Jul 10, 2024
July 10 (Reuters) - Novavax Inc ( NVAX ): * STATE STREET CORP REPORTS 4.32% PASSIVE STAKE IN NOVAVAX INC AS OF JUNE 30, 2024 VERSUS 12.11% AS OF APRIL 30, 2023 - SEC FILING Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved